Faralimomab Biosimilar – Anti-IFNA1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1217; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Faralimomab Biosimilar, also known as Anti-IFNA1 mAb, is a research grade antibody that has shown promising results in the treatment of various autoimmune diseases. This biosimilar is a monoclonal antibody that targets the interferon alpha 1 (IFNA1) protein, which plays a crucial role in the immune response and has been implicated in the pathogenesis of many autoimmune disorders. In this article, we will discuss the structure, activity, and potential applications of Faralimomab Biosimilar.
Faralimomab Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is produced by genetic engineering techniques that involve cloning and expression of the antibody gene in mammalian cells. The antibody consists of two heavy chains and two light chains, which are linked by disulfide bonds. The heavy chains contain a constant region (Fc) and a variable region (Fab), while the light chains only have a variable region. The variable regions of the antibody are responsible for binding to the target protein, IFNA1.
Faralimomab Biosimilar works by binding to the IFNA1 protein and inhibiting its activity. This protein is a type I interferon that is produced by immune cells in response to viral infections or other triggers. In healthy individuals, IFNA1 helps to fight off infections and regulate the immune response. However, in autoimmune diseases, the production of IFNA1 is dysregulated, leading to chronic inflammation and tissue damage. By targeting and blocking IFNA1, Faralimomab Biosimilar can help to reduce the inflammatory response and alleviate the symptoms of autoimmune diseases.
The binding of Faralimomab Biosimilar to IFNA1 also triggers a cascade of events that further suppress the immune response. This includes the recruitment of immune cells that can eliminate cells producing IFNA1, as well as the inhibition of other pro-inflammatory cytokines. This multi-pronged approach makes Faralimomab Biosimilar a potent therapeutic agent for autoimmune diseases.
Faralimomab Biosimilar is currently being studied for its potential use in various autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. These diseases are characterized by an overactive immune response and elevated levels of IFNA1. By targeting IFNA1, Faralimomab Biosimilar can help to reduce the symptoms and slow the progression of these diseases.
In addition to its potential use in autoimmune diseases, Faralimomab Biosimilar also shows promise in the treatment of certain types of cancer. IFNA1 has been shown to promote tumor growth and resistance to chemotherapy. By blocking IFNA1, Faralimomab Biosimilar can enhance the efficacy of chemotherapy and potentially inhibit the growth of cancer cells.
In summary, Faralimomab Biosimilar is a research grade antibody that targets the interferon alpha 1 protein. Its unique structure and mechanism of action make it a promising therapeutic agent for autoimmune diseases and cancer. Further research and clinical trials are needed to fully understand the potential of Faralimomab Biosimilar and its role in the treatment of these diseases.
Keywords: antibody, therapeutic target, Faralimomab Biosimilar, Anti-IFNA1 mAb, autoimmune diseases, IFNA1, monoclonal antibody, cancer, inflammation, immune response
ProteoGenix catalogue number PX-TA1217. For research use only.
Target: Faralimomab Biosimilar – Anti-IFNA1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Faralimomab Biosimilar – Anti-IFNA1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
